Statistik Asas
| LEI | 5493000KKX5VQ37Q2W83 |
| CIK | 1627281 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cellectis S.A. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 4, 2025 |
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates EXHIBIT 99.1 Cellectis Reports Second Quarter 2025 Financial Results & Business Updates Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phas |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 4, 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| August 4, 2025 |
Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the six month period ended June 30, 2025, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in U.S. dollar |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: August 4, 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| July 28, 2025 |
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025 EXHIBIT 99.1 Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second qua |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 28, 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| July 9, 2025 |
Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris, France July 9, 2025 CORRESP Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris, France July 9, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes RE: Cellectis S.A. Registration Statement on Form F-3 (File No. 333-288491) Dear Mr. Howes: In accordance with Rules 460 and 461 under the |
|
| July 2, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Registration Statement Form F-3 (Form Type) Cellectis S. |
|
| July 2, 2025 |
As filed with the Securities and Exchange Commission on July 2, 2025 F-3 Table of Contents As filed with the Securities and Exchange Commission on July 2, 2025 Registration No. |
|
| June 26, 2025 |
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 PRESS RELEASE Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 June 26, 2025 – New York (N. |
|
| June 26, 2025 |
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 EXHIBIT 99.1 Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 r |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: June 26, 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 26, 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| June 26, 2025 |
CELLECTIS ANNUAL SHAREHOLDERS MEETING June 26, 2025 CELLECTIS ANNUAL SHAREHOLDERS MEETING June 26, 2025 Ordinary Resolutions N° Resolution Result For Against Vote withhold Total votes Shares represented by the votes cast Percentage of the share capital represented by the votes cast Out of voting rights Null voting rights Quorum Votes % Votes % Votes % 1 approval of the annual financial statements for the financial year ended December 31. |
|
| May 21, 2025 |
CELLECTIS A corporation (“SA”) with a share capital of 5,014,561.35 euros Registered office: 8, rue de la Croix Jarry - 75013 Paris 428 859 052 T.C.R. Paris (the “Company”) NOTICE OF MEETING COMBINED GENERAL MEETING OF SHAREHOLDERS OF June 26, 2025 The shareholders are hereby informed that they are convened to the combined general meeting to be held on June 26, 2025 at 2:30 p.m. at the Biopark aud |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 21, 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: May 21, 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| May 21, 2025 |
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025 EXHIBIT 99.1 Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025 NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, |
|
| May 12, 2025 |
Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three month period ended March 31, 2025, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in U.S. dol |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: May 12, 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 12, 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| May 12, 2025 |
Cellectis Reports Financial Results for the First Quarter 2025 EXHIBIT 99.1 Cellectis Reports Financial Results for the First Quarter 2025 Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025 AstraZeneca partnership: R&D activities ongoing on three programs – one |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of princ |
|
| May 6, 2025 |
Cellectis to Report First Quarter Financial Results on May 12, 2025 EXHIBIT 99.1 Cellectis to Report First Quarter Financial Results on May 12, 2025 NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 |
|
| April 28, 2025 |
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting EXHIBIT 99.1 Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated n |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pri |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: March 31, 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| March 14, 2025 |
CELLECTIS S.A. COMPENSATION RECOUPMENT POLICY Exhibit 97.1 CELLECTIS S.A. COMPENSATION RECOUPMENT POLICY 1. Purpose; Overview. The purpose of this Compensation Recoupment Policy (this “Policy”) is to set forth the circumstances under which a Covered Executive will be required to repay or return Erroneously Awarded Compensation to Cellectis S.A. (together with its Affiliates, the “Company”). The Board has adopted this Policy in accordance with |
|
| March 14, 2025 |
EX-12.2 Exhibit 12.2 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Arthur Stril, certify that: 1. I have reviewed this annual report on Form 20-F/A of Cellectis S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fa |
|
| March 14, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section302 of the Sarbanes-Oxley Act of 2002 I, André Choulika, certify that: 1. I have reviewed this annual report on Form 20-F of Cellectis S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omi |
|
| March 14, 2025 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2023, Cellectis S.A. (the “Company,” “we,” “us,” and “our”) had the following series of securities registered pursuant to Section 12(b) of the Exchange Act: Title of Each Class Trading Symbol Name of each exchange on which registered American Depositary Shares, each representing 1 share, nomina |
|
| March 14, 2025 |
EX-12.1 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, André Choulika, certify that: 1. I have reviewed this annual report on Form 20-F/A of Cellectis S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material |
|
| March 14, 2025 |
CELLECTIS SA CHANGE IN CONTROL SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Exhibit 4.4 CELLECTIS SA CHANGE IN CONTROL SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION The Board of Directors of Cellectis S.A has adopted this Global Change in Control Severance Plan for the benefit of non-executive employees of the Company and its Affiliates, on the terms and conditions hereinafter stated. All capitalized terms used herein are defined in Section 1 hereof. SECTION 1. DEFINITIONS. |
|
| March 14, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section302 of the Sarbanes-Oxley Act of 2002 I, Arthur Stril, certify that: 1. I have reviewed this annual report on Form 20-F of CellectisS.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit t |
|
| March 14, 2025 |
EXHIBIT 13.1 Certification by the Principal Executive Officer pursuant to 18U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Cellectis S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, André Choulika, |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O |
|
| March 14, 2025 |
Consent of independent registered public accounting firm Exhibit 15.2 Consent of independent registered public accounting firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 No 333-204205) pertaining to the 2015 Stock Option Plan and the 2015 Free Share Plan of Cellectis S.A.; (2) Registration Statement (Form S-8 No 333-214884) pertaining to the 2016 Stock Option Plan of Cellec |
|
| March 14, 2025 |
INSIDER TRADING POLICY August 2020 revised on December 19, 2024 Exhibit 11.1 INSIDER TRADING POLICY August 2020 revised on December 19, 2024 Introduction The purpose of this Insider Trading Policy (this “Policy”) is to promote compliance with applicable French and United States federal and state securities laws and regulations (“Applicable Laws”) by Cellectis S.A. and its subsidiaries (collectively, the “Company”), and their respective directors, executive off |
|
| March 14, 2025 |
English version (for information purposes) Exhibit 1.1 CELLECTIS Corporation (société anonyme) with a share capital of 5,014,403.20 Registered office: 8 rue de la Croix Jarry, 75013 Paris. 428 859 052 R.C.S. Paris By-Laws As of March 3, 2025 EUI-1217258275v6 English version (for information purposes) 1. FORM The Company is a corporation (société anonyme), governed by Book II of the French commerci |
|
| March 14, 2025 |
EXHIBIT 13.2 Certification by the Principal Financial Officer pursuant to 18U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Cellectis S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bing Wang, Chie |
|
| March 14, 2025 |
Exhibit 4.34 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) is the type that the registrant treats as private and confidential. [***] CELLECTIS S.A. (IEU TI) european investment banK as Subscriber and CELLECTIS S.A. as Issuer Subscription AGREEMENT for warrants TO BE ISSUED BY CELLECTIS S.A.Sub dated 30 March 2 |
|
| March 14, 2025 |
Consent of independent registered public accounting firm Exhibit 15.2 Consent of independent registered public accounting firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 No 333-204205) pertaining to the 2015 Stock Option Plan and the2015 Free Share Plan of Cellectis S.A.; (2) Registration Statement (Form S-8 No 333-214884) pertaining to the 2016 Stock Option Plan ofCellecti |
|
| March 14, 2025 |
Consent of Independent Registered Public Accounting Firm EX-15.1 Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements Nos. 333-284302, 333-265826 on Form F-3 and Nos. 333- 284301, 333-273777, 333-267760, 333-258514, 333-227717, 333-222482, 333-214884, 333-204205 on Form S-8 of our reports dated March 13, 2025, with respect to the consolidated financial statement |
|
| March 14, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements Nos. 333-284302, 333-265826 on Form F-3 and Nos. 333-284301, 333-273777, 333-267760, 333-258514, 333-227717, 333-222482, 333-214884, 333-204205 on Form S-8 of our reports dated March 13, 2025, with respect to the consolidated financial statements of Cell |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 7, 2025 |
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 EXHIBIT 99.1 Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pri |
|
| February 24, 2025 |
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 EXHIBIT 99.1 Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cell engi |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| January 30, 2025 |
Information with respect to the Directors and Executive Officers of the Reporting Persons EX-99.2 2 tm254869d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Information with respect to the Directors and Executive Officers of the Reporting Persons Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of BPIFRANCE PARTICIPATIONS S.A. The name, business address and present principal occupation or employment of each of the |
|
| January 21, 2025 |
Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris, France January 21, 2025 Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris, France January 21, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory RE: Cellectis S.A. Registration Statement on Form F-3 (File No. 333-284302) Dear Mr. Drory: In accordance with Rules 460 and 461 under the Sec |
|
| January 15, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cellectis S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2)(3) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Ordinary Shares, €0.0 |
|
| January 15, 2025 |
Exhibit 99.1 CELLECTIS 2024 STOCK OPTION PLAN SUMMARY Page 1. Purposes of the Plan 1 2. Definitions 1 3. Shares subject to the Plan 3 4. Administration of the Plan 4 (a) procedure 5 (b) powers of the Administrator 5 (c) effects of Administrator’s decisions 5 5. Limitations 5 6. Term of the Plan 5 7. Term of the Options 5 8. Options exercise price and consideration 6 (a) subscriptio |
|
| January 15, 2025 |
As filed with the Securities and Exchange Commission on January 15, 2025 Table of Contents As filed with the Securities and Exchange Commission on January 15, 2025 Registration No. |
|
| January 15, 2025 |
2024 FREE SHARES PLAN Approved by the Board of Directors on August 6, 2024 Exhibit 99.2 CELLECTIS 2024 FREE SHARES PLAN Approved by the Board of Directors on August 6, 2024 TABLE OF CONTENTS 1. IMPLEMENTATION OF THE FREE SHARES PLAN 3 2. DEFINITIONS 3 3. PURPOSE 4 4. BENEFICIARIES 4 5. NOTICE OF THE ALLOCATION OF THE SHARES 5 6. ACQUISITION PERIOD 5 6.1. Principle 5 6.2 Internal mobility 6 6.3 Disability 6 6.4 Decease 6 6.5 Retirement 6 7. HOLDING PERIOD 6 7.1 Pri |
|
| January 15, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Registration Statement Form F-3 (Form Type) Cellectis S. |
|
| January 15, 2025 |
As filed with the Securities and Exchange Commission on January 15, 2025. As filed with the Securities and Exchange Commission on January 15, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CELLECTIS S.A. (Exact name of registrant as specified in its charter) France Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| December 10, 2024 |
EXHIBIT 99.1 Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therap |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| November 5, 2024 |
EXHIBIT 99.1 Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical |
|
| November 4, 2024 |
Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and nine month periods ended September 30, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are present |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: November 4, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
|
| October 30, 2024 |
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 EXHIBIT 99.1 Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third qua |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 30, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
|
| October 22, 2024 |
EXHIBIT 99.1 Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that they will be showc |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 22, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 to Report on Form 6-K (Film No. 241179819) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: September 11, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de |
|
| September 11, 2024 |
Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six month periods ended June 30, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| September 3, 2024 |
EXHIBIT 99.1 Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a scie |
|
| August 26, 2024 |
EXHIBIT 99.1 Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an artic |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 26, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 7, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| August 7, 2024 |
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer EXHIBIT 99.1 Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: August 6, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| August 6, 2024 |
Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six month periods ended June 30, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in |
|
| August 1, 2024 |
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment EXHIBIT 99.1 FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 1, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| July 25, 2024 |
EXHIBIT 99.1 FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1 There is an urgent need to develop new therapies for ALL for patients who are not |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 25, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| June 28, 2024 |
CELLECTIS ANNUAL SHAREHOLDERS MEETING – June 28. 2024 VOTE RESULTS Exhibit 99.1 CELLECTIS ANNUAL SHAREHOLDERS MEETING – June 28. 2024 VOTE RESULTS Ordinary Resolutions NB Resolution Result For Against Vote whithhold Total votes Shares represented by the votes cast Percentage of the share capital represented by the votes cast Out of voting rights Null voting rights Quorum Votes % Votes % Votes % 1 approval of the annual financial statements for the financial year |
|
| June 28, 2024 |
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 EXHIBIT 99.1 Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 r |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of prin |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: June 28, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| June 20, 2024 |
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing EXHIBIT 99.1 Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscrip |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 20, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| June 12, 2024 |
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications EXHIBIT 99.1 Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientifi |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of prin |
|
| June 4, 2024 |
EXHIBIT 99.1 Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of prin |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of princ |
|
| May 29, 2024 |
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024 EXHIBIT 99.1 Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024 NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 28, 2 |
|
| May 28, 2024 |
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 EXHIBIT 99.1 Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter |
|
| May 28, 2024 |
EXHIBIT 99.1 Cellectis Reports Financial Results for First Quarter 2024 · Cellectis announced completion of the additional equity investment of $140M by AstraZeneca · Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 · Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) - Cellectis ( |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 28, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: May 28, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| May 28, 2024 |
as Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month periods ended March 31, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in U.S. |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of princ |
|
| May 24, 2024 |
Exhibit 99.1 CELLECTIS A corporation (“SA”) with a share capital of 4,997,776.75 euros Headquarters: 8, rue de la Croix Jarry - 75013 Paris 428 859 052 T.C.R. Paris (the “Company”) NOTICE OF MEETING COMBINED GENERAL MEETING OF SHAREHOLDERS OF JUNE 28, 2024 The shareholders are hereby informed that they are convened to the combined general meeting to be held on June 28, 2024 at 2:30 p.m. at the Bio |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: May 24, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Cellectis S.A. (Name of Issuer) Ordinary Shares, nominal value €0.05 per share (Title of Class of Securities) 15117K103 (American Depositary Shares, each representing one Ordinary Share) (CUSIP Number) Sophie Paquin Bpifrance Participations S.A. 6-8, bou |
|
| May 6, 2024 |
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca EXHIBIT 99.1 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to devel |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of princ |
|
| May 3, 2024 |
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer EX-99.1 Exhibit 99.1 PRESS RELEASE Cellectis Appoints Arthur Stril as Interim Chief Financial Officer New York, NY - May 2, 2024 – Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the resignation of Mr. Bing Wang from his position of th |
|
| May 3, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Of the Securities Exchange Act of 1934 Date of Report: May 2, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 29, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 No. 333-204205) pertaining to the 2015 Stock Option Plan and the 2015 Free Share Plan of Cellectis S.A.; (2) Registration Statement (Form S-8 No 333-214884) pertaining to the 2016 Stock Option Plan of Celle |
|
| April 29, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section302 of the Sarbanes-Oxley Act of 2002 I, Bing Wang, certify that: 1. I have reviewed this annual report on Form 20-F of CellectisS.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to s |
|
| April 29, 2024 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2023, Cellectis S.A. (the “Company,” “we,” “us,” and “our”) had the following series of securities registered pursuant to Section 12(b) of the Exchange Act: Title of Each Class Trading Symbol Name of each exchange on which registered American Depositary Shares, each representing 1 share, nomina |
|
| April 29, 2024 |
English version (for information purposes) Exhibit 1.1 CELLECTIS Corporation (société anonyme) with a share capital of 3,597,776.75 Registered office: 8 rue de la Croix Jarry, 75013 Paris. 428 859 052 R.C.S. Paris By-Laws As of March 28, 2024 English version (for information purposes) ARTICLE 1 - FORM The Company is a corporation (société anonyme), governed by Book II of the French commercial code |
|
| April 29, 2024 |
CELLECTIS S.A. COMPENSATION RECOUPMENT POLICY Exhibit 97.1 CELLECTIS S.A. COMPENSATION RECOUPMENT POLICY 1. Purpose; Overview. The purpose of this Compensation Recoupment Policy (this “Policy”) is to set forth the circumstances under which a Covered Executive will be required to repay or return Erroneously Awarded Compensation to Cellectis S.A. (together with its Affiliates, the “Company”). The Board has adopted this Policy in accordance with |
|
| April 29, 2024 |
EXHIBIT 13.1 Certification by the Principal Executive Officer pursuant to 18U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Cellectis S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, André Choulika, |
|
| April 29, 2024 |
Exhibit 4.33 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) is the type that the registrant treats as private and confidential. [***] CELLECTIS S.A. (IEU TI) european investment banK as Subscriber and CELLECTIS S.A. as Issuer Subscription AGREEMENT for warrants TO BE ISSUED BY CELLECTIS S.A.Sub dated 30 March 2 |
|
| April 29, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section302 of the Sarbanes-Oxley Act of 2002 I, André Choulika, certify that: 1. I have reviewed this annual report on Form 20-F of Cellectis S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omi |
|
| April 29, 2024 |
EXHIBIT 13.2 Certification by the Principal Financial Officer pursuant to 18U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Cellectis S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bing Wang, Chie |
|
| April 29, 2024 |
EY CHANGE IN AUDITORS 16F ITEM LETTER Exhibit 15.2 EY CHANGE IN AUDITORS 16F ITEM LETTER Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen, We have read Item 16F. Change in Registrant’s Certifying Accountant on page 126 of Form 20-F dated April 29, 2024, of Cellectis S.A. and are in agreement with the statements contained in paragraphs one, four, and six. Regarding the registrant's stateme |
|
| April 22, 2024 |
EXHIBIT 99.1 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseases Non-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 2 |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pri |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pri |
|
| April 10, 2024 |
EXHIBIT 99.1 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publ |
|
| April 8, 2024 |
EXHIBIT 99.1 Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene ther |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pri |
|
| February 14, 2024 |
EX-1 2 ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the |
|
| February 14, 2024 |
SC 13G/A 1 cellectis13ga2.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cellectis S.A. (Name of Issuer) Ordinary Shares (Title of Class of Securities) 15117K103 (CUSIP Number) Long Focus Capital Management LLC 207 Calle Del Parque A&M Tower, 8th Floor San Juan, PR 00912 (787) 333-0240 ( |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing)* CELLECTIS S.A. (Name of Issuer) Ordinary Shares, €0.05 nominal value per share (Title of Class of Securities) 15117K103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 16, 2024 |
EXHIBIT 99.1 Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene ther |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 16, 2024 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
|
| December 22, 2023 |
CELLECTIS Shareholders Meeting December 22, 2023 Vote Results Exhibit 99.1 CELLECTIS Shareholders Meeting December 22, 2023 Vote Results Extraordinary Resolutions NB Resolution Result For Against Vote withhold Total votes Shares represented by the votes cast Percentage of the share capital represented by the votes cast Out of vote voting rights Null voting rights Quorum Votes % Votes % Votes % 1 Creation of a class of preferred shares referred to as “Class A |
|
| December 22, 2023 |
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 EXHIBIT 99.1 Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Of the Securities Exchange Act of 1934 Date of Report: December 22, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| December 22, 2023 |
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 Exhibit 99.2 PRESS RELEASE Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 December 22, 2023 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark aud |
|
| December 5, 2023 |
Exhibit 99.1 Time Sensitive Materials Depositary’s Notice of Combined Ordinary and Extraordinary General Meeting of Cellectis S.A. ADSs: American Depositary Shares (“ADSs”). ADS CUSIP No.: 15117K103. ADS Record Date: November 28, 2023. French Record Date: December 20, 2023 (12:01 P.M. Paris time). This is the time at which ADS Holders are required under French Law to hold their interest in the ord |
|
| December 5, 2023 |
Exhibit 99.2 Combined Ordinary and Extraordinary General Meeting The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on December 18, 2023 for action to be taken. 2023 VOTING INSTRUCTIONS AMERICAN DEPOSITARY SHARES Cellectis S.A. (the “Company”) ADS CUSIP No.: 15117K103. ADS Record Date: November 28, 2023. French Record Da |
|
| December 5, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Of the Securities Exchange Act of 1934 Date of Report: December 5, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address |
|
| November 17, 2023 |
Cellectis’ Shareholders Meeting to be Held on December 22, 2023 EXHIBIT 99.1 Cellectis’ Shareholders Meeting to be Held on December 22, 2023 NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Bio |
|
| November 17, 2023 |
Cellectis’ Shareholders Meeting to be Held on December 22, 2023 Exhibit 99.2 PRESS RELEASE Cellectis’ Shareholders Meeting to be Held on December 22, 2023 November 17, 2023 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET a |
|
| November 17, 2023 |
Exhibit 99.1 English language translation For information purpose only CELLECTIS French société anonyme with share capital of EUR 3,587,560.05 Registered office: 8, rue de la Croix Jarry - 75013 Paris 428 859 052 R.C.S. Paris (the “Company”) NOTICE OF COMBINED EXTRAORDINARY AND ORDINARY SHAREHOLDERS’ GENERAL MEETING OF DECEMBER 22, 2023 Shareholders are hereby informed that they are invited to att |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Of the Securities Exchange Act of 1934 Date of Report: November 17, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| November 16, 2023 |
CLLS / Cellectis - ADR / ASTRAZENECA PLC - SC 13D/A Activist Investment CUSIP No. 15117K103 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cellectis S.A. (Name of Issuer) Ordinary shares, nominal value of €0.05 per ordinary share (Title of Class of Securities) 15117K103 (CUSIP Number) Adrian Kemp AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridg |
|
| November 15, 2023 |
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca Exhibit 99.1 Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca • Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023. • Extraordinary shareholders’ meeting of Cellectis to be held on or around December 22, 2023 to approve such investment. Ne |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Of the Securities Exchange Act of 1934 Date of Report: November 15, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| November 13, 2023 |
CLLS / Cellectis - ADR / Bpifrance Participations SA - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cellectis S.A. (Name of Issuer) Ordinary Shares, nominal value €0.05 per share (Title of Class of Securities) 15117K103 (American Depositary Shares, each representing one Ordinary Share) (CUSIP Number) Charlotte Sorin Bpifrance Participations S.A. 6-8, b |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Of the Securities Exchange Act of 1934 Date of Report: November 9, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| November 9, 2023 |
Exhibit 99.3 Confidential CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. MEMORANDUM OF UNDERSTANDING BETWEEN CELLECTIS S.A. AND ASTRAZENECA HOLDINGS B.V. DATED NOVEMBER 1, 2023 This memorandum of understanding is made on |
|
| November 9, 2023 |
CLLS / Cellectis - ADR / ASTRAZENECA PLC - SC 13D Activist Investment SC 13D 1 tm2330279d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 Cellectis S.A. (Name of Issuer) Ordinary shares, nominal value of €0.05 per ordinary share (Title of Class of Securities) 15117K103 (CUSIP Number) Adrian Kemp AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge |
|
| November 9, 2023 |
Exhibit 99.2 Confidential CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. NOVEMBER 1, 2023 CELLECTIS S.A. ASTRAZENECA HOLDINGS B.V. INITIAL INVESTMENT AGREEMENT CONTENTS CLAUSE PAGE 1. Subscription 1 2. Use of proceeds 2 3 |
|
| November 9, 2023 |
Exhibit 99.1 Confidential CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. JOINT RESEARCH AND COLLABORATION AGREEMENT BY AND BETWEEN CELLECTIS S.A. AND ASTRAZENECA IRELAND LIMITED DATED NOVEMBER 1, 2023 TABLE OF CONTENTS Ar |
|
| November 9, 2023 |
EX-1 2 tm2330279d1ex1.htm EXHIBIT 1 EXHIBIT 1 CUSIP No. 15117K103 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing state |
|
| November 6, 2023 |
EX-99.1 2 clls-ex991.htm EX-99.1 Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidate |
|
| November 6, 2023 |
EXHIBIT 99.1 Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023 · Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I NATHALI-01 Trial evaluating UCART20x22 in r/r B-cell NHL to be presented at ASH 65th Annual meeting. Clinica |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: November 6, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 6, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 2, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
|
| November 2, 2023 |
EXHIBIT 99.1 Cellectis to Present Preliminary Results of NATHALI01 and Updated Results of the BALLI01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cel |
|
| November 1, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Of the Securities Exchange Act of 1934 Date of Report: November 1, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address |
|
| November 1, 2023 |
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca EX-99.1 Exhibit 99.1 Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca • Collaboration leverages Cellectis’ gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate products • Cellectis to receive up to $245M in cash (up to $220M equity investment and $25M upfront payment), with potential for additional mi |
|
| November 1, 2023 |
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023 EXHIBIT 99.1 Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023 NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third qua |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 1, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
|
| October 31, 2023 |
EX-12.1 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, André Choulika, certify that: 1. I have reviewed this annual report on Form 20-F/A of Cellectis S.A.; and 2. Based on my knowledge, this report does not contain any untrue statement of a mater |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 31, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
|
| October 31, 2023 |
EX-12.2 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bing Wang, certify that: 1. I have reviewed this annual report on Form 20-F/A of Cellectis S.A.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material f |
|
| October 31, 2023 |
Exhibit 99.1 Translation for information purposes only CELLECTIS French société anonyme (corporation) with share capital of 2,779,188.40 euros Registered office : 8 rue de la Croix Jarry, 75013 Paris Paris Trade and Companies Registry no. 428 859 052 BYLAWS UPDATED AS OF JUNE 27, 2023 Copy certified as true to the original by the Chief Executive Officer André Choulika Translation for information p |
|
| October 31, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SEC |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Of the Securities Exchange Act of 1934 Date of Report: October 31, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| October 31, 2023 |
EXHIBIT 99.1 Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 24, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
|
| October 24, 2023 |
EXHIBIT 99.1 Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announc |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| October 12, 2023 |
EXHIBIT 99.1 Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1) NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| September 27, 2023 |
EXHIBIT 99.1 Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 to Report on Form 6-K (Film No. 231147864) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: September 5, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de l |
|
| September 5, 2023 |
Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and six-month periods ended June 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in |
|
| August 7, 2023 |
Exhibit 99.2 CELLECTIS 2023 FREE SHARES PLAN Approved by the Board of Directors on August 7, 2023 TABLE OF CONTENTS 1. IMPLEMENTATION OF THE FREE SHARES PLAN 3 2. DEFINITIONS 3 3. PURPOSE 4 4. BENEFICIARIES 4 5. NOTICE OF THE ALLOCATION OF THE SHARES 5 6. ACQUISITION PERIOD 5 6.1. Principle 5 6.2 Internal mobility 6 6.3 Disability 6 6.4 Decease 6 6.5 Retirement 6 7. HOLDING PERIOD 6 7.1 Principle |
|
| August 7, 2023 |
Cellectis Provides Full Report for Second Quarter 2023 Financial Results EXHIBIT 99.1 Cellectis Provides Full Report for Second Quarter 2023 Financial Results NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) - Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the release of the full report of the financial result |
|
| August 7, 2023 |
EX-99.1 Exhibit 99.1 CELLECTIS 2023 STOCK OPTION PLAN SUMMARY Page 1. Purposes of the Plan 1 2. Definitions 1 3. Shares subject to the Plan 3 4. Administration of the Plan 3 (a) procedure (b) powers of the Administrator (c) effects of Administrator’s decisions 5. Limitations 5 6. Term of the Plan 5 7. Term of the Options 5 8. Options exercise price and consideration 6 (a) subscription or purchase |
|
| August 7, 2023 |
EX-99.1 Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and six-month periods ended June 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are pres |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: August 7, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| August 7, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cellectis S. |
|
| August 7, 2023 |
As filed with the Securities and Exchange Commission on August 7, 2023. S-8 As filed with the Securities and Exchange Commission on August 7, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CELLECTIS S.A. (Exact name of registrant as specified in its charter) France Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| August 3, 2023 |
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023 EXHIBIT 99.1 Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023 Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 3, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of |
|
| July 27, 2023 |
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023 EXHIBIT 99.1 Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023 NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) - Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the secon |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 27, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| July 12, 2023 |
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors EXHIBIT 99.1 Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) - Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that during the annual shareholders meeting held on Jun |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of prin |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: June 29, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| June 29, 2023 |
CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 27, 2023 VOTE RESULTS EX-99.2 Exhibit 99.2 CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 27, 2023 VOTE RESULTS Ordinary Resolutions NB Resolution Result For Against Vote withhold Total votes Shares represented by the votes cast Percentage of the share capital represented by the votes cast Out of vote voting rights Null voting rights Quorum Votes % Votes % Votes % 1 Approval of the annual financial statements for the f |
|
| June 29, 2023 |
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023 Exhibit 99.1 PRESS RELEASE Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023 June 28, 2023 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CE |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of prin |
|
| June 28, 2023 |
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023 EXHIBIT 99.1 Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023 NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 9, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| June 9, 2023 |
EXHIBIT 99.1 Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023 NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated cl |
|
| June 5, 2023 |
EXHIBIT 99.1 Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL, presented at an oral session Encouraging data presented on gene editing process using Cellectis TALEN® t |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 5, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| June 1, 2023 |
CLXT / Calyxt Inc / Cellectis S.A. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Calyxt, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13173L107 (CUSIP Number) Marie-Bleuenn Terrier General Counsel Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 ( |
|
| May 31, 2023 |
EXHIBIT 99.1 Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to d |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 31, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: May 22, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| May 22, 2023 |
EX-99.1 Exhibit 99.1 CELLECTIS A corporation (“SA”) with a share capital of 2.779.188,40 euros Headquarters: 8, rue de la Croix Jarry - 75013 Paris 428 859 052 T.C.R. Paris (the “Company”) NOTICE OF MEETING COMBINED GENERAL MEETING OF SHAREHOLDERS OF JUNE 27, 2023 The shareholders are hereby informed that they are convened to the combined general meeting to be held on June 27, 2023 at 2:30 p.m. at |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 17, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pr |
|
| May 17, 2023 |
EXHIBIT 99.1 Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023 NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, toda |
|
| May 12, 2023 |
EXHIBIT 99.1 Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of princ |
|
| May 11, 2023 |
EXHIBIT 99.1 Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023 BALLI-01 (evaluating UCART22) abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL population NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of princ |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Date of Report: May 4, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pri |
|
| May 4, 2023 |
EX-99.1 Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month period ended March 31, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of princ |
|
| May 2, 2023 |
EXHIBIT 99.1 Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-edi |
|
| April 27, 2023 |
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023 EXHIBIT 99.1 Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023 NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter ended March 31 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pri |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of pri |
|
| April 24, 2023 |
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab EXHIBIT 99.1 Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab Cellectis demonstrated that the addition of alemtuzumab to the lymphodepletion regimen was associated with prolonged lymphodepletion and significantly higher cell expansion and clinical activity NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: C |
|
| April 17, 2023 |
EXHIBIT 99.1 Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing |
|
| April 17, 2023 |
6-K 1 f6k041723.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 17, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France + |
|
| April 11, 2023 |
EXHIBIT 99.1 Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22 UCART22 is currently the most advanced allogeneic CAR T-cell product in development for relapsed or refractory B-cell acute lymphoblastic leukemia The BALLI-01 study (evaluating UCART22) is actively enrolling patients with relapsed or refractory B-cell ALL after FCA lymph |
|
| April 11, 2023 |
6-K 1 f6k041123.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 11, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France + |
|
| April 4, 2023 |
EX-99.1 Exhibit 99.1 Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million New York, NY – April 4, 2023 – Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving ce |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Of the Securities Exchange Act of 1934 Date of Report: April 4, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of prin |
|
| March 14, 2023 |
EX-13.1 EXHIBIT 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Cellectis S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, André |
|
| March 14, 2023 |
EXHIBIT 99.1 Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop |
|
| March 14, 2023 |
Description of Securities registered under Section 12 of the Exchange Act EX-2.3 Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2022, Cellectis S.A. (the “Company,” “we,” “us,” and “our”) had the following series of securities registered pursuant to Section 12(b) of the Exchange Act: Title of Each Class Trading Symbol Name of each exchange on which registered American Depositary Shares, each representing 1 share, |
|
| March 14, 2023 |
EX-4.26 Exhibit 4.26 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) is the type that the registrant treats as private and confidential. EIB Internal Classification Corporate Use [***] CELLECTIS (IEU TI) Finance Contract between the European Investment Bank and CELLECTIS 28 December 2022 WHEREAS: 2 ARTICLE 1 3 1 |
|
| March 14, 2023 |
EX-4.1(4) EXHIBIT 4.1.4 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) is the type that the registrant treats as private and confidential. OTC Agreement Number: [***] Case Number: [***] Cellectis Ref.: [***] FOURTH AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT THIS FOURTH AMENDMENT TO EXCLUSIVE PATENT LICENSE |
|
| March 14, 2023 |
By-laws (Statuts) of the registrant (English translation) EX-1.1 2 d423150dex11.htm EX-1.1 Exhibit 1.1 CELLECTIS French société anonyme (corporation) with share capital of € 2,779,188.40 Registered office : 8 rue de la Croix Jarry, 75013 Paris Paris Trade and Companies Registry no. 428 859 052 BYLAWS Updated as of February 8, 2023 Copy certified as true to the original by the Chief Executive Officer André Choulika ARTICLE 1 - FORM The Company is a corpor |
|
| March 14, 2023 |
EX-13.2 EXHIBIT 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Cellectis S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bing W |
|
| March 14, 2023 |
6-K 1 f6k031423.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 14, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France + |
|
| March 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 14, 2023 |
EX-12.2 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bing Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Cellectis S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or |
|
| March 14, 2023 |
Form of Change in Control Agreement Exhibit 4.3 FORM OF [FIRST AMENDMENT TO THE] CHANGE IN CONTROL AGREEMENT [This First Amendment to the Change in Control Agreement (the “Amendment”)] / [This Change in Control Agreement (the “Agreement”)] is made as of , 2022, by and between [EXECUTIVE NAME] (the “Executive”) and [INSERT] (the “Company”). RECITALS A. [The Company and Executive are parties to that certain Change in Control Agreement |
|
| March 14, 2023 |
EX-12.1 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, André Choulika, certify that: 1. I have reviewed this annual report on Form 20-F of Cellectis S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fa |
|
| March 14, 2023 |
Consent of Ernst & Young et Autres (PCAOB # 1704) Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 No. 333-204205) pertaining to the 2015 Stock Option Plan and the 2015 Free Share Plan of Cellectis S.A.; (2) Registration Statement (Form S-8 No 333-214884) pertaining to the 2016 Stock Option Plan of Celle |
|
| March 8, 2023 |
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results EXHIBIT 99.1 Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluatin |
|
| March 8, 2023 |
6-K 1 f6k030823.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 8, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +3 |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 6, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| March 6, 2023 |
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) - Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, |
|
| March 1, 2023 |
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023 EXHIBIT 99.1 Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023 NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quart |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 1, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of p |
|
| February 14, 2023 |
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP EX-2 3 ex2.htm EXHIBIT 2 Exhibit 2 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Long Focus Capital Management, LLC, a Delaware single member limited liability company Long Focus Capital Master, LTD., a Cayman Islands limited company Condagua, LLC, a Delaware single member limited liability company John B. Helmers, a United States citizen A. Glenn Helmers, a United States citizen |
|
| February 14, 2023 |
Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 14, 2023 |
CLLS / Cellectis S.A. / Bpifrance Participations SA - SC 13D/A Activist Investment SC 13D/A 1 tm236516d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cellectis S.A. (Name of Issuer) Ordinary Shares, nominal value €0.05 per share (Title of Class of Securities) 15117K103 (American Depositary Shares, each representing one Ordinary Share) (CUSIP Number) Sophie Paqu |
|
| February 14, 2023 |
CLLS / Cellectis S.A. / Long Focus Capital Management, Llc - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cellectis S.A. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 15117K103 (CUSIP Number) Long Focus Capital Management LLC 207 Calle Del Parque A&M Tower, 8th Floor San Juan, PR 00912 (787) 333-0240 (Name, Address and Telephone Number of Pers |
|
| February 8, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: February 8, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address |
|
| February 8, 2023 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) - Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cel |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 7, 2023 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address o |
